Core Insights - Hyperion DeFi, Inc. has established a cryptocurrency treasury reserve focused on the HYPE token and is the first publicly listed U.S. company to implement decentralized finance (DeFi) strategies on the Hyperliquid blockchain [1][3] - The company has accumulated over 1.5 million HYPE tokens and has formed a co-branded validator with Kinetiq, enhancing its on-chain engagement strategy [1][6] - The FDA registration for the Optejet User Filled Device (UFD) is on track for September 2025, indicating ongoing development in ophthalmic digital technologies [1][3] Financial Performance - For Q2 2025, the net loss attributable to common stockholders was $8.8 million, or $2.50 per share, an improvement from a net loss of $11.1 million, or $16.65 per share, in Q2 2024 [4][17] - Research and development expenses decreased by 85% to $0.7 million in Q2 2025, down from $4.6 million in Q2 2024, primarily due to a reduction in headcount following the termination of the CHAPERONE study [5] - General and administrative expenses increased by 104% to $7.7 million in Q2 2025, compared to $3.8 million in Q2 2024, driven by a one-time stock-based compensation grant and higher professional fees [7] Corporate Developments - The company closed a private placement financing of $50 million and successfully established its cryptocurrency treasury reserve [6] - A corporate rebranding was implemented, changing the name from Eyenovia, Inc. to Hyperion DeFi, Inc., reflecting its new focus on DeFi and blockchain technologies [6] - The company hosted a corporate update webinar to discuss its transformation and the potential of using blockchain-native assets like HYPE for scalable, yield-generating products [6] Asset and Cash Position - As of June 30, 2025, the company's unrestricted cash and cash equivalents were $7.5 million, a significant increase from $2.1 million at the end of 2024 [8] - Total assets as of June 30, 2025, amounted to $55.7 million, compared to $3.7 million at the end of 2024, indicating substantial growth in the company's asset base [15][16]

"This is a moment our entire team has been working toward for years," said Dean Burns, CEO of Ocumetics. "Every milestone we've achieved in recent weeks reflects the dedication, expertise, and sheer determination of our people and partners. We're now just a few days away from transforming the future of vision correction with the first implantation of our groundbreaking accommodating intraocular lens. I couldn't be prouder of what our team has accomplished." Calgary, Alberta – TheNewswire - August 12, 2025 - ...

Core Insights - Eyenovia, Inc. has increased its total holdings of HYPE tokens to 1,306,452 by acquiring an additional 265,872 tokens at an average price of $34.83 each [1][2] - The company aims to leverage its HYPE holdings to participate in ecosystem growth initiatives and generate yield at the protocol level [2][5] - HYPE is the native token of the Hyperliquid platform, which is designed for high-frequency trading and includes features like on-chain perpetual futures and spot order books [3][4] Company Overview - Eyenovia is a pioneering digital ophthalmic technology company and the first publicly listed U.S. company to build a strategic treasury of HYPE [5] - The company is focused on revolutionizing topical eye treatment while providing shareholders with access to the Hyperliquid ecosystem, which is noted for its rapid growth and high revenue generation [5] - Eyenovia is also developing the Optejet User Filled Device (UFD) for various ophthalmic liquids, aimed at improving treatment compliance and outcomes for patients [6]

Core Insights - Eyenovia has acquired a significant position in HYPE tokens, making it the first Nasdaq-listed company to operate a validator on the Hyperliquid blockchain [1][2] - The company has successfully closed a $50 million private placement (PIPE) to fund the acquisition of 1,040,584.5 HYPE tokens at an average price of approximately $34 per token [2][3] - Eyenovia is on track for FDA registration of its Optejet User Filled Device (UFD) by September 2025, with ongoing discussions for potential partnerships [1][5] Company Strategy - The acquisition of HYPE tokens is part of Eyenovia's new cryptocurrency treasury reserve strategy aimed at creating long-term shareholder value through digital currency adoption [3] - The company plans to initiate its own network validator to support the Hyperliquid blockchain and access HYPE staking yield [2][3] - Eyenovia is expected to change its name and ticker to "Hyperion DeFi" and "HYPD" pending Board approval [4] Product Development - Development of the Optejet UFD is progressing as planned, with verification and validation activities set to begin next month [5] - The Optejet is designed for various topical ophthalmic liquids, enhancing treatment compliance and outcomes for patients with chronic front-of-the-eye diseases [9] Hyperliquid Platform Overview - Hyperliquid is a layer one blockchain optimized for high-frequency trading, featuring on-chain perpetual futures and spot order books [6] - HYPE, the native token of Hyperliquid, provides utility through reduced trading fees and increased referral bonuses, with over 25 million HYPE sequestered by the blockchain as of June 2025 [7]